FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031291235> ?p ?o ?g. }

• W3031291235 abstract "Abstract Background The present study was aimed to enhance the solubility and dissolution of BCS class II drug, telmisartan (TEM), by nanoformulation approach. Several attempts were made to develop a nanosuspension by bottom-up and top-down techniques. In our study, we found in situ nanoamorphization technique to be incompatible and hence was not selected for further development of nanoformulation. Bottom-up techniques such as anti-solvent precipitation and emulsification solvent evaporation methods failed to reduce the size of the drug to nanoform by HPMC E15 and PVP K-25 at 1500–2000 rpm but resulted in micron-sized particles. Results However, the acid-base neutralization method has produced nanosuspension with a particle size of 243.9 nm and 0.119 PDI. Formulation and analytical development were carried out by statistical factorial design using the Design-Expert software (version 11.0). The nanosuspensions remained stable even after 90 days without any aggregations with particle size 338.1 nm and PDI 0.146. Zeta potential of optimized formulation was found to be − 16.2 mV. Drug content and its release were estimated by the developed and validated in-house HPLC method. In vitro drug diffusion studies on the optimized formulation have shown a drug release of 82.6% by the end of 3 h, whereas plain drug suspension has shown only 42.8% release, indicating a 2-fold increase of drug diffusion with nanosuspension. Ex vivo drug permeation studies performed using excised goat gastric mucosa revealed much faster permeation of TEM from nanosuspension than the plain drug suspension. Conclusions Hence, from the results, it can be concluded that TEM, when formulated by acid-base neutralization method as a nanosuspension, leads to enhanced solubility, dissolution, and stability." @default.
• W3031291235 created "2020-06-05" @default.
• W3031291235 creator A5012932567 @default.
• W3031291235 creator A5028799975 @default.
• W3031291235 creator A5045912377 @default.
• W3031291235 creator A5050606520 @default.
• W3031291235 creator A5062712331 @default.
• W3031291235 creator A5078479398 @default.
• W3031291235 date "2020-05-20" @default.
• W3031291235 modified "2023-10-12" @default.
• W3031291235 title "A Design of Experiment (DoE) based approach for development and optimization of nanosuspensions of telmisartan, a BCS class II antihypertensive drug" @default.
• W3031291235 cites W1042084257 @default.
• W3031291235 cites W1968054977 @default.
• W3031291235 cites W1975505033 @default.
• W3031291235 cites W2000252319 @default.
• W3031291235 cites W2028724994 @default.
• W3031291235 cites W2028883574 @default.
• W3031291235 cites W2055335182 @default.
• W3031291235 cites W2101531267 @default.
• W3031291235 cites W2106647432 @default.
• W3031291235 cites W2129980493 @default.
• W3031291235 cites W2140067957 @default.
• W3031291235 cites W2163196876 @default.
• W3031291235 cites W2329954946 @default.
• W3031291235 cites W2406580062 @default.
• W3031291235 doi "https://doi.org/10.1186/s43094-020-00032-2" @default.
• W3031291235 hasPublicationYear "2020" @default.
• W3031291235 type Work @default.
• W3031291235 sameAs 3031291235 @default.
• W3031291235 citedByCount "4" @default.
• W3031291235 countsByYear W30312912352021 @default.
• W3031291235 countsByYear W30312912352022 @default.
• W3031291235 crossrefType "journal-article" @default.
• W3031291235 hasAuthorship W3031291235A5012932567 @default.
• W3031291235 hasAuthorship W3031291235A5028799975 @default.
• W3031291235 hasAuthorship W3031291235A5045912377 @default.
• W3031291235 hasAuthorship W3031291235A5050606520 @default.
• W3031291235 hasAuthorship W3031291235A5062712331 @default.
• W3031291235 hasAuthorship W3031291235A5078479398 @default.
• W3031291235 hasBestOaLocation W30312912351 @default.
• W3031291235 hasConcept C105795698 @default.
• W3031291235 hasConcept C126838900 @default.
• W3031291235 hasConcept C147789679 @default.
• W3031291235 hasConcept C155574463 @default.
• W3031291235 hasConcept C155672457 @default.
• W3031291235 hasConcept C169222746 @default.
• W3031291235 hasConcept C171250308 @default.
• W3031291235 hasConcept C178790620 @default.
• W3031291235 hasConcept C185592680 @default.
• W3031291235 hasConcept C187530423 @default.
• W3031291235 hasConcept C192562407 @default.
• W3031291235 hasConcept C2779716603 @default.
• W3031291235 hasConcept C2780035454 @default.
• W3031291235 hasConcept C2780471494 @default.
• W3031291235 hasConcept C33923547 @default.
• W3031291235 hasConcept C41625074 @default.
• W3031291235 hasConcept C43617362 @default.
• W3031291235 hasConcept C50670333 @default.
• W3031291235 hasConcept C55493867 @default.
• W3031291235 hasConcept C71924100 @default.
• W3031291235 hasConcept C84393581 @default.
• W3031291235 hasConcept C86181022 @default.
• W3031291235 hasConcept C88380143 @default.
• W3031291235 hasConcept C98274493 @default.
• W3031291235 hasConceptScore W3031291235C105795698 @default.
• W3031291235 hasConceptScore W3031291235C126838900 @default.
• W3031291235 hasConceptScore W3031291235C147789679 @default.
• W3031291235 hasConceptScore W3031291235C155574463 @default.
• W3031291235 hasConceptScore W3031291235C155672457 @default.
• W3031291235 hasConceptScore W3031291235C169222746 @default.
• W3031291235 hasConceptScore W3031291235C171250308 @default.
• W3031291235 hasConceptScore W3031291235C178790620 @default.
• W3031291235 hasConceptScore W3031291235C185592680 @default.
• W3031291235 hasConceptScore W3031291235C187530423 @default.
• W3031291235 hasConceptScore W3031291235C192562407 @default.
• W3031291235 hasConceptScore W3031291235C2779716603 @default.
• W3031291235 hasConceptScore W3031291235C2780035454 @default.
• W3031291235 hasConceptScore W3031291235C2780471494 @default.
• W3031291235 hasConceptScore W3031291235C33923547 @default.
• W3031291235 hasConceptScore W3031291235C41625074 @default.
• W3031291235 hasConceptScore W3031291235C43617362 @default.
• W3031291235 hasConceptScore W3031291235C50670333 @default.
• W3031291235 hasConceptScore W3031291235C55493867 @default.
• W3031291235 hasConceptScore W3031291235C71924100 @default.
• W3031291235 hasConceptScore W3031291235C84393581 @default.
• W3031291235 hasConceptScore W3031291235C86181022 @default.
• W3031291235 hasConceptScore W3031291235C88380143 @default.
• W3031291235 hasConceptScore W3031291235C98274493 @default.
• W3031291235 hasIssue "1" @default.
• W3031291235 hasLocation W30312912351 @default.
• W3031291235 hasOpenAccess W3031291235 @default.
• W3031291235 hasPrimaryLocation W30312912351 @default.
• W3031291235 hasRelatedWork W2023942206 @default.
• W3031291235 hasRelatedWork W2069651938 @default.
• W3031291235 hasRelatedWork W2137694438 @default.
• W3031291235 hasRelatedWork W2350983338 @default.
• W3031291235 hasRelatedWork W2354469736 @default.
• W3031291235 hasRelatedWork W2393759938 @default.
• W3031291235 hasRelatedWork W3000823499 @default.
• W3031291235 hasRelatedWork W3203575380 @default.

• next